Nektar Therapeutics

NASDAQ:NKTR

Biotechnology

Healthcare
$34.42 -2.04%

-$1.24 today

Market cap
$987.44M
Beta
1.15
P/E (TTM)
-9.3
EPS (TTM)
-$6.39
52W Low $8.27High $109.00

Volume 0.71M

Average 1.00M

NKTR Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Nektar TherapeuticsNASDAQ: NKTR

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures growth accelerates

Q2 FY2026 capital expenditures of $112K (cash outflow) rose 202.7% year over year, ahead of the -77.5% change in trailing-twelve-month capital expenditures. Sequentially, it rose 522.2% from the prior quarter. Over 3 fiscal years it compounded at -68.9% a year.

Context

  • Capital expenditures amounted to 0.3% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +202.7% holds above the trailing-twelve-month pace of -77.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$112K+522.2% QoQ
Last fiscal yearDec 2025
-$171K-88.4% YoY
LTMJun 2026
-$262K-77.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+202.7%——
1 year-88.4%——
3-year CAGR-68.9%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(171K) USD
Year-over-year change
+88.4%

Capital Expenditures vs competitors

How NKTR compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -77.5% is the lowest of 8, against a peer median of -58.3%.
  • Capital expenditures amounts to 0.5% of revenue for NKTR, versus a peer median of 1.5%.
NKTR Competitors
Capital Expenditures for NKTR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMCRImmunocore Holdings plcLTM Mar 2026$5.82M USD+15.4%+13.6%1.5%
IMTXImmatics N.V.LTM Mar 2026€4.36M EUR-58.3%+0.4%11.7%
XNCRXencor, Inc.LTM Jun 2026$2.47M USD-62.7%-58.3%2.4%
MGNXMacroGenics, Inc.LTM Mar 2026$1.73M USD-37.7%-19.2%1.1%
RCUSArcus Biosciences, Inc.LTM Jun 2026$1M USD-66.7%-30.7%0.9%
NKTRNektar TherapeuticsLTM Jun 2026$262K USD-77.5%-68.9%0.5%
ANLAdlai Nortye Ltd.LTM Jun 2024$237K USD—-47.1%3.7%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$229K USD+536.1%-13.5%—
IPHAInnate Pharma S.A.FY2025€134.47K EUR-65.6%-50.7%4.8%
CGENCompugen Ltd.LTM Dec 2025$0 USD—-14.3%0.0%
CHRSCoherus Oncology, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding NKTR) —-58.3%-19.2%1.5%

Competitors are the stored peer set for NKTR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(523.84M)(368.2M)(276.06M)(118.96M)(164.08M)
Depreciation & Amortization14.15M13.03M7.82M4.39M(4.49M)
Deferred Income Tax8.02M2.71M(140K)00
Stock-Based Compensation94.67M57.32M33.39M21.61M12.65M
Change in Working Capital(23.08M)492K(19.8M)(6.24M)(37.02M)
Accounts Receivables12.4M16.51M4.78M(3.05M)0
Inventory(509K)(3.4M)699K497K0
Accounts Payables(11.69M)3.1M(2.88M)2.67M(625K)
Other Working Capital(23.27M)(15.72M)(22.39M)(6.36M)(36.39M)
Other Non-Cash Items17.41M(9.36M)62.19M(76.51M)(15.58M)
Operating Cash Flow(412.66M)(304.01M)(192.61M)(175.71M)(208.51M)
Capital Expenditures(14.99M)(5.68M)(865K)(1.47M)(171K)
Acquisitions (Net)(217.77M)13.2M065.39M(697K)
Purchases of Investments(960.69M)(467.91M)(511.7M)(261.71M)(285.01M)
Sales of Investments1.18B826.23M650.88M340.36M284.68M
Other Investing Activities217.77M01.25M00
Investing Cash Flow202.78M365.84M139.56M142.57M(1.2M)
Debt Repayment00000
Common Stock Issued33.24M758K30K30.12M180.57M
Common Stock Repurchased000(3M)0
Dividends Paid00000
Other Financing Activities3M750K015M0
Financing Cash Flow36.24M1.51M30K42.12M180.57M
Effect of Forex Changes(92K)(327K)62K(4K)6K
Net Change in Cash(173.74M)63.01M(52.95M)8.98M(29.14M)
Free Cash Flow(427.65M)(309.68M)(193.47M)(177.18M)(208.68M)

Nektar Therapeutics

NASDAQ:NKTR

Intrinsic Alpha fair value

Locked

Current Price

$34.42

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.